A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours

被引：0
|
作者：
de Bono, J. S. [1 ,2 ]
Lord, S. [3 ]
Yap, C. [4 ]
Miranda, S. [5 ]
Veal, G. J. [6 ]
Chandran, K. [7 ]
Paschalis, A. [8 ]
Peron, C. [9 ]
Rekowski, J. [10 ]
Gurel, B. [5 ]
Paisley, D. [11 ]
McGuigan, L. [12 ]
Ingram, P. J. [13 ]
Kwek, K. Y. [14 ]
Halbert, G. [12 ]
Westwood, N. B. [12 ]
Griffin, A. E. [11 ]
Kostaras, L. [11 ]
Boyd-Kirkup, J. D. [15 ]
Walter, H. S. [11 ]
机构：
[1] Inst Canc Res, Prostate Canc Targeted Therapies Grp, Sutton, England
[2] Royal Marsden Hosp, Sutton, England
[3] Univ Oxford, Dept Oncol, Oxford, England
[4] ICR Inst Canc Res North Site, Clin Trials Biostat Dept, Sutton, England
[5] ICR Inst Canc Res, Clin Studies Canc Biomarkers, London, England
[6] Newcastle Univ, Newcastle Univ Ctr Canc, Newcastle Upon Tyne, England
[7] Royal Marsden Hosp NHS Fdn, Prostate Canc Targeted Therapies Grp, Sutton, England
[8] ICR Inst Canc Res, Clin Studies, London, England
[9] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford, England
[10] ICR Inst Canc Res, Clin Trials & Stat Unit, London, England
[11] CRUK Canc Res UK, Ctr Drug Dev, London, England
[12] Canc Res UK, Ctr Drug Dev, London, England
[13] Hummingbird Biosci Pte Ltd Temasek Lifesci Labs, Singapore, Singapore
[14] Hummingbird Biosci, Clin Dev, Singapore, Singapore
[15] Hummingbird Biosci Pte Ltd Temasek Lifesci Labs, Res, Singapore, Singapore
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1873
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687P
引用
收藏
页码：S479 / S480
页数：2
相关论文
共 50 条
  • [31] Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
    Metzger Filho, O.
    Leone, J. P.
    Li, T.
    Tan-Wasielewski, Z.
    Trippa, L.
    Barry, W. T.
    Younger, J.
    Lawler, E.
    Walker, L.
    Freedman, R. A.
    Tolaney, S. M.
    Krop, I
    Winer, E. P.
    Lin, N. U.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1231 - 1239
  • [32] Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
    Jaenne, Pasi A.
    Boss, David S.
    Camidge, D. Ross
    Britten, Carolyn D.
    Engelman, Jeffrey A.
    Garon, Edward B.
    Guo, Feng
    Wong, Steven
    Liang, Jane
    Letrent, Stephen
    Millham, Robert
    Taylor, Ian
    Eckhardt, S. Gail
    Schellens, Jan H. M.
    CLINICAL CANCER RESEARCH, 2011, 17 (05) : 1131 - 1139
  • [33] A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours
    U Lassen
    D L Nielsen
    M Sørensen
    L Winstedt
    T Niskanen
    Y Stenberg
    S Pakola
    J-M Stassen
    S Glazer
    British Journal of Cancer, 2012, 106 : 678 - 684
  • [34] A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours
    Lassen, U.
    Nielsen, D. L.
    Sorensen, M.
    Winstedt, L.
    Niskanen, T.
    Stenberg, Y.
    Pakola, S.
    Stassen, J-M
    Glazer, S.
    BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 678 - 684
  • [35] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Sarina A. Piha-Paul
    Analía Azaro
    Hendrik Tobias Arkenau
    Do-Youn Oh
    Matthew D. Galsky
    Sumanta Kumar Pal
    Kensuke Hamada
    Yaohua He
    Ikuo Yamamiya
    Karim A Benhadji
    Antoine Hollebecque
    Investigational New Drugs, 2021, 39 : 1324 - 1334
  • [36] Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
    Wakui, Hiroshi
    Yamamoto, Noboru
    Nakamichi, Shinji
    Tamura, Yousuke
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 511 - 516
  • [37] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Piha-Paul, Sarina A.
    Azaro, Analia
    Arkenau, Hendrik Tobias
    Oh, Do-Youn
    Galsky, Matthew D.
    Pal, Sumanta Kumar
    Hamada, Kensuke
    He, Yaohua
    Yamamiya, Ikuo
    Benhadji, Karim A.
    Hollebecque, Antoine
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1324 - 1334
  • [38] Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
    Hiroshi Wakui
    Noboru Yamamoto
    Shinji Nakamichi
    Yousuke Tamura
    Hiroshi Nokihara
    Yasuhide Yamada
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 511 - 516
  • [39] Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors
    Bensch, Frederike
    Lamberts, Laetitia E.
    Lub-de Hooge, Marjolijn N.
    van Scheltinga, Anton G. T. Terwisscha
    de Jong, Johan R.
    Gietema, Jourik A.
    Schroder, Carolien P.
    Smeenk, Michiel M.
    Jacob, Wolfgang
    Abiraj, Keelara
    Wolf, Michaela
    Adessi, Celine
    Meneses-Lorente, Georgina
    Zajac, Magdalena
    Weisser, Martin
    Brouwers, Adrienne H.
    De Vries, Elisabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors.
    Berlin, J.
    Keedy, V. L.
    Janne, P. A.
    Yee, L.
    Rizvi, N. A.
    Jin, X.
    Copigneaux, C.
    Hettmann, T.
    Beaupre, D. M.
    LoRusso, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345